No live calls today · full consensus board · graded history
Price (daily close, 2026-08-24)
Recent news
| 2026-08-25 | Gossamer Bio secures up to $250 million financing to advance Seralutinib towards FDA review - Indian Pharma Post · Indian Pharma Post |
| 2026-08-25 | SCHEDULE 13D/A - Gossamer Bio, Inc. (0001728117) (Subject) · sec_edgar_current |
| 2026-08-24 | Gossamer Bio announces $250m in funding to advance seralutinib - Pharmaceutical Business review - · Pharmaceutical Business review - |
| 2026-08-24 | Gossamer Bio announces $250m in funding to advance seralutinib · Pharmaceutical Technology |
| 2026-08-21 | Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval - Pulse 2.0 · Pulse 2.0 |
| 2026-08-21 | Gossamer Bio Slips as $250M Financing Hinges on FDA Approval - Gossamer Bio (NASDAQ:GOSS) - Benzinga · Benzinga |
How grading works: every call is locked before the open and scored on the session's open→close move — see the methodology.
Open Fortivio.AI →Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。